Targeting cancer immune evasion with anti-FOLR1 antibody-drug conjugate potentiates anti–PD-1 efficacy in colorectal cancer
Loss of major histocompatibility complex class I (MHC-I) antigen presentation in tumor cells drives immune evasion and resistance to immune checkpoint blockade (ICB) in colorectal cancer (CRC). To identify therapeutic targets reversing this, we conducted fluorescence-activated cell sorting–based CRISPR activation screens using a druggable genome library and identified folate receptor α (FOLR1) as a top negative regulator. FOLR1 was heterogeneously expressed in CRC tumors but undetectable in adjacent normal tissues. High expression of FOLR1 predicted a poor ICB response, enhanced cancer stemness, and unfavorable patient outcomes. Functional assays showed that FOLR1 promoted CRC stemness–associated properties and fostered an immunosuppressive tumor microenvironment (TME) with impaired CD8 + T cell infiltration and cytotoxicity, thereby driving tumor progression. Proteomic analyses revealed that FOLR1 stabilized the lactyltransferase AARS1 (alanyl-tRNA synthetase 1), which lactylated signal transducer and activator of transcription 1 (STAT1) at lysine-193 (K193), facilitating its interaction with TCPTP (T cell protein-tyrosine phosphatase) and inducing STAT1 dephosphorylation at tyrosine-701. Consequently, impaired STAT1 signaling down-regulated MHC-I and up-regulated MYC proto-oncogene protein (c-MYC), facilitating evasion of T cell surveillance and enhancing cancer stemness. The anti-FOLR1 antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) exhibited potent activity against FOLR1-positive CRC cells, reprogramming the TME to an immune-active status. Combining IMGN853 with anti–PD-1 (programmed cell death protein–1) therapy boosted antitumor immunity, sensitized tumors to immunotherapy, and induced robust tumor regression in vivo. Our findings support anti-FOLR1 ADC as a clinically actionable approach to overcome immune evasion and unlock immunotherapy efficacy in CRC.
Authors
- Ping Lan (ORCID: https://orcid.org/0000-0002-8901-8498)
- Shubiao Ye (ORCID: https://orcid.org/0000-0002-4203-4546)
- Xiaosheng He (ORCID: https://orcid.org/0000-0002-8346-4972)
- Xin‐Yuan Guan (ORCID: https://orcid.org/0000-0002-4485-6017)
- Xiaona Fang (ORCID: https://orcid.org/0000-0001-5325-4686)
- 林振森
- Min Li (ORCID: https://orcid.org/0009-0003-9757-6822)
- Yongxin Xie (ORCID: https://orcid.org/0009-0005-5321-1826)
- Lei Li (ORCID: https://orcid.org/0000-0001-9910-5600)
- Qian Yan (ORCID: https://orcid.org/0000-0001-6549-8135)
- Xueli Zhang (ORCID: https://orcid.org/0000-0001-5963-9261)
- Jing Yu (ORCID: https://orcid.org/0009-0005-8220-0931)
- Yu Zhang (ORCID: https://orcid.org/0000-0003-3643-6589)
- Qishan Liu (ORCID: https://orcid.org/0009-0007-5920-3696)
- Jianning Song
- Yanping Ma
- Yaqing Du (ORCID: https://orcid.org/0009-0007-3909-6176)
- Yuhai Yuan
- Chen Jiang
- Guiwei He
- Siqi Chen (ORCID: https://orcid.org/0009-0008-4939-756X)
Institutions
- Nanchang University (CN)
- Sun Yat-sen University (CN)
- Jinan University (CN)
- Chinese Academy of Sciences (CN)
- Westlake University (CN)
- Sixth Affiliated Hospital of Sun Yat-sen University (CN)
- First Affiliated Hospital of Jiangxi Medical College (CN)
- Sun Yat-sen Memorial Hospital (CN)
- Shenzhen Bay Laboratory (CN)
- Shenzhen Institutes of Advanced Technology (CN)
- Sun Yat-sen University Cancer Center (CN)
- First Affiliated Hospital of Nanchang University (CN)
- State Key Laboratory of Oncology in South China (CN)
- Shenzhen Medical Academy of Research and Translation (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- Science Translational Medicine
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1126/scitranslmed.aed2106
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Sun Yat-sen University
- Natural Science Foundation of Guangdong Province
- Guangzhou Municipal Science and Technology Project
- National Key Research and Development Program of China
- Fundamental Research Funds for the Central Universities